Research and Clinical Trials

Title  
TESARO 4010-01-001: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Brief Description  
- To evaluate the safety and tolerability of TSR-042 using Common Terminology Criteria for Adverse Events (CTCAE v.4.03) in patients with advanced solid tumors - To evaluate the antitumor activity of TSR-042 in patients with advanced solid tumors, in terms of objective response rate (ORR) as assessed by the Investigators using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Breast
Status  
OPEN
Start Date  
07/06/2017
IRB Number  
00021131
Principal Investigator  
Brown, Jubilee
Contact Name  
Mandy Campbell

For More Information, Contact  Mandy  , Campbell
Phone:  980-442-2340 Fax:    
Email:  Amanda.Setzer@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close